Nuoheng Jianhua (09969): The National Medical Products Administration approves MINJUVI (TAFASITAMAB) in combination with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma in adult patients in China.

Zhtng Cijng APP Xn, Nuchng Jinhu (09969) Fb gnggo, Guji Yopn Jind Gunl J (NMPA) y pzh Minjuvi (tafasitamab)(y kun bxing CD19 de Fc jigu yuhu de rnyunhu xboli dnd kngt) y li nd'n linh zhlio (zhhu sh Minjuvi dnyo zhlio) b shh zu zt gn xbo yzh (ASCT) de ff hu nnzh x h gun xbo lnfn lnmu (DLBCL) de chngnin hunzh. Zh sh Zhnggu shukun hup yngy zhlio ff hu nnzh x DLBCL de CD19 kngt. According to Zhtng Cijng APP, Nuchng Jinhu (09969) has announced that the National Medical Products Administration (NMPA) has approved Minjuvi (tafasitamab) for use in combination with lenalidomide (followed by Minjuvi monotherapy) in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not suitable for autologous stem cell transplant (ASCT). This is the first CD19 antibody approved in China for the treatment of relapsed or refractory DLBCL.